Developing novel therapies for the treatment of atrial fibrillation.
Xention is developing novel therapies for the treatment of atrial fibrillation using its proprietary platform of ion channel drug discovery and development. The Company is developing drug candidates that modulate two novel, but well characterised, ion channels and expects to develop breakthrough products in this area of huge unmet medical need.
- CEO Tim Brears, PhD
- Industry Biotech